Background and Purpose-Because of its association with atrial fibrillation and heart failure, we hypothesized that amino terminal pro-B-type natriuretic peptide (NT-proBNP) would identify a subgroup of patients from the Warfarin-Aspirin Recurrent Stroke Study, diagnosed with inferred noncardioembolic ischemic strokes, where anticoagulation would be more effective than antiplatelet agents in reducing risk of subsequent events. Methods-NT-proBNP was measured in stored serum collected at baseline from participants enrolled in Warfarin-Aspirin Recurrent Stroke Study, a previously reported randomized trial. Relative effectiveness of warfarin and aspirin in preventing recurrent ischemic stroke or death over 2 years was compared based on NT-proBNP concentrations. Results-About 95% of 1028 patients with assays had NT-proBNP below 750 pg/mL, and among them, no evidence for treatment effect modification was evident. For 49 patients with NT-proBNP >750 pg/mL, the 2-year rate of events per 100 person-years was 45.9 for the aspirin group and 16.6 for the warfarin group, whereas for 979 patients with NT-proBNP ≤750 pg/mL, rates were similar for both treatments. For those with NT-proBNP >750 pg/mL, the hazard ratio was 0.30 (95% confidence interval: 0.12-0.84; P=0.021) significantly favoring warfarin over aspirin. A formal test for interaction of NT-proBNP with treatment was significant (P=0.01). Conclusions-For secondary stroke prevention, elevated NT-proBNP concentrations may identify a subgroup of ischemic stroke patients without known atrial fibrillation, about 5% based on the current study, who may benefit more from anticoagulants than antiplatelet agents. 
F
or secondary prevention after ischemic stroke, only a few subgroups of patients have been identified, most notably those with atrial fibrillation, among whom anticoagulants are more effective than antiplatelet agents at reducing subsequent ischemic events. Increased levels of the hormone brain (or B-type) natriuretic peptide (BNP), or its inert cometabolite amino terminal pro-B-type natriuretic peptide (NT-proBNP), 1 are associated with prevalent and incident atrial fibrillation and heart failure. 2, 3 Patients with elevated BNP or NT-proBNP levels around the time of their incident stroke are more likely to have a cardioembolic mechanism identified, [4] [5] [6] [7] [8] [9] [10] [11] [12] to have a worse outcome from their stroke, [12] [13] [14] [15] [16] and to have an increased risk of future events, such as recurrent ischemic stroke 17 and death. [12] [13] [14] [18] [19] [20] [21] [22] We hypothesized that a cutoff of BNP or NT-proBNP levels would exist above which anticoagulation would be superior to antiplatelet agents-namely that the relative efficacy of these treatments would be modified by BNP or NT-proBNP levels. Seeking to test this hypothesis, we analyzed NT-proBNP in serum collected at baseline as part of the Antiphospholipid Antibodies and Stroke Study (APASS), 23 a prospective cohort study within the Warfarin-Aspirin Recurrent Stroke Study (WARSS). 24 In this double-blind trial, the relative effectiveness of warfarin and aspirin in preventing recurrent ischemic stroke or death in patients with a prior inferred noncardioembolic ischemic stroke was compared. ratio, 1.4-2.8) to aspirin (325 mg/day) for prevention of the primary outcome, first to occur of recurrent ischemic stroke or death from any cause, within 2 years. 24 In WARSS, eligible patients were aged 30 to 85 years, were considered acceptable candidates for warfarin therapy, had had an ischemic stroke within the previous 30 days, and had scores of 3 or more on the Glasgow Outcome Scale. On this scale, a score of 3 indicates severe disability; a score of 4, moderate disability; and a score of 5, minimal or no disability. Patients were ineligible if they had: a baseline INR above the normal range of 1.4; a stroke that was because of a procedure or that was attributed to high-grade carotid stenosis for which surgery was planned; or a stroke associated with an inferred cardioembolic source. Most of the last group had atrial fibrillation at the time of stroke.
In APASS, bloods were obtained from consenting WARSS participants at baseline before randomization and treatment. 23 We learned from APASS investigators that blood specimens remained from approximately 1000 participants. Serum was assayed for NT-proBNP at the University of Maryland using an approach identical to that described previously. 2 Briefly, NT-proBNP was measured on the Elecsys 2010 system (Roche Diagnostics, Indianapolis, IN). The coefficient of variation for the NT-proBNP assay was 2% to 5% during the testing period, and its analytic measurement range was 5 to 35 000 pg/mL, where 1 pg/mL equals 0.118 pmol/L. 1 All samples were stored at -70°C to -80°C and were thawed before testing (maximum of 3 freeze-thaw cycles). This assay has been shown to be reliable on stored specimens, and measurements of NT-proBNP using this assay do not change after 5 freeze-thaw cycles. 25 No information about the patient from whom the blood came was available to those performing the assays. On those patients with NT-proBNP levels assayed, the baseline clinical and follow-up data, including treatment assignment, were obtained from the WARSS coordinating center at Columbia University. All of the participants in the original studies provided written informed consent, including for their blood to be studied for future markers of increased risk of stroke, and none of the data mentioned above included personal identifiers.
Analyses compared the relative effectiveness of warfarin and aspirin in preventing the primary outcome of first to occur of recurrent ischemic stroke or death within 2 years of randomization. Among the participants with NT-proBNP assayed, characteristics were compared between the 2 treatment groups, using the χ 2 test for categorical variables and the t test for continuous variables and excluding those with unknown values. To show that the patients with NT-proBNP assayed were representative of all patients in WARSS, these same characteristics were similarly compared between those with and without NTproBNP assayed. A probability value less than 0.05 was considered significant.
Because the distribution of NT-proBNP was highly skewed to the right, we began by stratifying NT-proBNP at 750 pg/mL, representing about the 95th percentile. We chose this arbitrary value because the literature does not suggested a specific cutoff for such analyses. We made this decision without any analyses that included outcome data. To evaluate treatment effect modification, we used a Cox model, including age, sex, the treatment variable, the strata variable, and interaction between treatment and strata. Because the interaction test was statistically significant (P=0.01) for the 750 pg/mL cutoff, the treatments were compared separately for each stratum using the Cox proportional hazard model controlling for age, sex, and the natural logarithm of NT-proBNP as a continuous variable. The latter variable was included in these models because it was a predictor of outcome within each stratum and could increase the power of the test for treatment effect. For descriptive purposes, Kaplan-Meier cumulative event rate curves were displayed for each stratum comparing the 2 treatments. Also, for descriptive purposes, curves were generated with a cubic spline smoother for each treatment group relating NTproBNP levels to the probability of the primary outcome. Analyses were performed with Stata 11 (StataCorp LP, College Station, TX).
Results
Overall, the mean level for NT-proBNP was 220 pg/mL (standard deviation=663), and the median was 75 pg/mL (interquartile range=32-185). The median time between stroke onset and blood draw was 13 days (interquartile range=8-23). The 2 treatment groups were similar on the characteristics listed in Table 1 , except for the warfarin group being significantly older than the aspirin group. In addition, patients enrolled in WARSS with and without NT-proBNP assayed were similar, without any significant differences in the characteristics listed in Table 1 .
For NT-proBNP ≤750 pg/mL, the 2-year rate of events per 100 person-years was 6.8 for the aspirin group and 8.5 for the warfarin group, whereas for NT-proBNP >750 pg/mL, the rate was 45.9 for the aspirin group and 16.6 for the warfarin group ( Table 2 ). In adjusted Cox proportional hazard models, for those with NT-proBNP ≤750 pg/mL, the hazard ratio was 1.21 (95% confidence interval, 0.87-1.69; P=0.243), favoring aspirin over warfarin, but not significantly. For those with NT-proBNP >750 pg/mL, the hazard ratio was 0.30 (95% confidence interval, 0.12-0.84; P=0.021), significantly favoring warfarin over aspirin ( Table 2) . Statistically controlling individually for the time between the stroke onset and blood draw, and the other factors listed in Table 1 did not alter these conclusions.
For descriptive purposes, the Kaplan-Meier cumulative event rate curves for the 2 treatment groups are shown in Figure 1 based on the cutoff of 750 pg/mL for NT-proBNP. Although warfarin and aspirin were comparable in preventing the primary outcome of recurrent ischemic stroke or death among those with NT-proBNP ≤750 pg/mL ( Figure 1A) , warfarin was more effective than aspirin among those with NT-proBNP >750 pg/mL ( Figure 1B) .
Finally, smoothed curves were generated for both treatments to estimate the probability of recurrent ischemic stroke or death over 2 years, as a function of NT-proBNP levels. Figure 2 shows that, at lower levels of NT-proBNP, the probability of the primary outcome increased with increasing levels of NT-proBNP for those on either aspirin or warfarin. At higher levels of NT-proBNP, the probability in those on warfarin declined markedly, whereas the probability in those on aspirin continued to rise. The small number of patients with high levels of NT-proBNP prevented precise identification of the best cutoff, and also imposes a need for caution in interpreting the substantial differences between treatments at the higher levels of NT-proBNP.
Discussion
We hypothesized that NT-proBNP concentrations could be used to define a subgroup of inferred noncardioembolic ischemic stroke patients who would benefit more from anticoagulants than from antiplatelet agents in preventing recurrent ischemic stroke or death over 2 years after their stroke. These data from the WARSS and its collaborative study, APASS, suggest that such a subgroup may exist with NT-proBNP levels >750 pg/ mL, representing about 5% of the patients in whom assays were performed. Patients in this subgroup had a significantly reduced risk of recurrent ischemic stroke or death when treated with warfarin compared with aspirin, with a point estimate of the relative risk reduction of 70%.
The benefit of warfarin over aspirin in these patients may arise because the elevated NT-proBNP is a marker for a subgroup of patients with heart failure and sinus rhythm who may
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March 2013 NT-proBNP indicates amino terminal pro-B-type natriuretic peptide. *For patients with NT-proBNP assayed, none of the characteristics differed significantly by treatment groups, except for age (P<0.05). Considering all patients in WARSS, none of the characteristics differed significantly between those with and without NT-proBNP assayed. In one patient, the quantity of the sample was insufficient to allow the assay to be performed successfully; therefore, subsequent analyses were based on 1028 patients. benefit more than others from anticoagulation. Additional analyses from a recent large trial 26 may help to identify such a subgroup. In the meantime, BNP and NT-proBNP levels are being evaluated to optimize therapy in outpatients with chronic heart failure. 27 Elevated NT-proBNP is also a marker for patients at high risk of atrial fibrillation. In the Cardiovascular Health Study, a large cohort study of elderly people followed for cardiovascular outcomes, the risk of developing incident atrial fibrillation was increased in those with elevated NT-proBNP, but not during the initial 2 years. Follow-up in WARSS was a maximum of 2 years. Had it been longer, perhaps a level of NT-proBNP <750 pg/mL would have been evident, where warfarin would have been more effective than aspirin in preventing recurrent ischemic stroke or death. Finally, prolonged cardiac rhythm monitoring was not performed in WARSS but may have identified episodic atrial fibrillation, as has been shown by others, 28 especially in those with elevated NT-proBNP. Unfortunately, which patient in WARSS may have developed atrial fibrillation during the 2-year follow-up is unknown.
Our analyses were driven by our prespecified hypothesis that warfarin would be superior to aspirin in those with 
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elevated NT-proBNP. The results are subject to the criticism that other cutoffs might have been both more or less statistically significant, but we stuck with the original choice so as not to bias our results. The scarcity of events in the upper tail of the distribution of NT-proBNP precludes: defining the optimal cutoff; examining the outcomes of stroke and death separately; and evaluating the effect of ischemic stroke subtypes. Furthermore, these results come from analyses in a subset of patients from the WARSS trial who may differ in some unknown way from others entered into that trial. Also, those who were entered into the WARSS trial may not be representative of all such ischemic stroke patients. Many patients in whom a cardioembolic source was suspected but not confirmed may not have been entered into the trial because of a clinician's conviction that anticoagulation was indicated, especially over the years that the trial was conducted between 1993 and 2000. Finally, the findings may be confounded by some other factor or factors that were not balanced between the 2 treatment groups, despite randomization. Although the results of these secondary analyses raise a strong possibility that warfarin may be superior to aspirin in those with high-NT-proBNP and be equally or less efficacious in those with lower values, these findings require replication before recommendations can be made to measure BNP or NT-proBNP after ischemic stroke and to base treatment decisions on the results. A randomized trial to confirm these findings would face a major challenge in identifying eligible patients. Although BNP and NT-proBNP levels are known to fall after an acute ischemic stroke, 14, 15, 19, [29] [30] [31] the optimal timing for levels to be assayed in such a trial is unknown, as is the value of repeated measures. In WARSS and APASS, bloods were collected at baseline, and patients needed to be randomized within 30 days of the ischemic stroke onset. In these analyses, the time from stroke onset to blood draw did not affect these results.
Levels of NT-proBNP may have implications for primary as well as secondary stroke prevention. Bloods were assayed for NT-proBNP in the recently reported trial of warfarin versus dabigatran for primary stroke prevention in patients with atrial fibrillation. 32 Investigators found that, even among those participants all of whom had atrial fibrillation, NT-proBNP was associated with an increased risk of stroke, especially among those in the highest quartile defined as NT-proBNP >1402 pg/ mL. The corollary to our question of secondary stroke prevention is whether low-NT-proBNP would identify a subgroup of patients with atrial fibrillation but without stroke, where antiplatelet agents would not be inferior to anticoagulants.
For secondary stroke prevention, NT-proBNP measurements may identify a subgroup of ischemic stroke patients without known atrial fibrillation, about 5% of those with assays in the current study, who may benefit more from anticoagulants than from antiplatelet agents. Replication of these findings supporting such a role for NT-proBNP is needed. The utility and timing of serial measurements of NT-proBNP in influencing treatment decisions aimed at primary or secondary stroke prevention is unknown and also worthy of investigation.
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